EA201692213A1 - Мицеллярный нанокомплекс - Google Patents

Мицеллярный нанокомплекс

Info

Publication number
EA201692213A1
EA201692213A1 EA201692213A EA201692213A EA201692213A1 EA 201692213 A1 EA201692213 A1 EA 201692213A1 EA 201692213 A EA201692213 A EA 201692213A EA 201692213 A EA201692213 A EA 201692213A EA 201692213 A1 EA201692213 A1 EA 201692213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
micelle
micellar
micellar nanocomplex
nanocomplex
polymer
Prior art date
Application number
EA201692213A
Other languages
English (en)
Other versions
EA035820B1 (ru
Inventor
Курисава Мотоичи
Юнвонсоонторн Нуннарпас
Джеки Я. Ин
Джоо Эун Чун
Ки Хюн Бае
Мин-хан Тан
Эстер Ли
Original Assignee
Эйдженси Фор Сайенс, Текнолоджи Энд Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйдженси Фор Сайенс, Текнолоджи Энд Рисерч filed Critical Эйдженси Фор Сайенс, Текнолоджи Энд Рисерч
Publication of EA201692213A1 publication Critical patent/EA201692213A1/ru
Publication of EA035820B1 publication Critical patent/EA035820B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
    • C08G65/3315—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
    • C08G65/3315—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic
    • C08G65/3317—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic phenolic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3318—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C08G65/3326—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/18—Manufacture of films or sheets
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/02—Starch; Degradation products thereof, e.g. dextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Abstract

Настоящее изобретение относится к мицеллярным нанокомплексам и к способу их изготовления. Мицеллярный нанокомплекс включает мицеллу и вещество, инкапсулированное в мицелле, при этом мицелла включает конъюгат полимер-флавоноид, в котором полимер связан с В-кольцом флавоноида. Мицеллярный нанокомплекс может найти полезное применение в качестве системы доставки лекарственных веществ.
EA201692213A 2014-05-09 2015-05-08 Мицеллярный нанокомплекс, способ его изготовления, конъюгат, способ лечения EA035820B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201402244S 2014-05-09
PCT/SG2015/050104 WO2015171079A1 (en) 2014-05-09 2015-05-08 A micellar nanocomplex

Publications (2)

Publication Number Publication Date
EA201692213A1 true EA201692213A1 (ru) 2017-06-30
EA035820B1 EA035820B1 (ru) 2020-08-17

Family

ID=54392771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692213A EA035820B1 (ru) 2014-05-09 2015-05-08 Мицеллярный нанокомплекс, способ его изготовления, конъюгат, способ лечения

Country Status (18)

Country Link
US (2) US10052307B2 (ru)
EP (1) EP3139915B1 (ru)
JP (1) JP6307631B2 (ru)
KR (2) KR102102093B1 (ru)
CN (1) CN106659708B (ru)
AU (1) AU2015256667C1 (ru)
BR (1) BR112016026260A2 (ru)
CA (1) CA2948460C (ru)
CU (1) CU24520B1 (ru)
EA (1) EA035820B1 (ru)
ES (1) ES2847602T3 (ru)
IL (1) IL248632B (ru)
MX (1) MX2016014606A (ru)
SA (1) SA516380256B1 (ru)
SG (1) SG11201609333YA (ru)
UA (1) UA118479C2 (ru)
WO (1) WO2015171079A1 (ru)
ZA (1) ZA201608424B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041830B1 (en) * 2013-09-03 2023-10-25 Agency For Science, Technology And Research Polymer-flavonoid conjugates and hydrogels for biomedical applications
US10052307B2 (en) 2014-05-09 2018-08-21 Agency For Science, Technology And Research Micellar nanocomplex
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
CN106511362B (zh) * 2015-09-15 2020-11-17 广东省人民医院 一种防治动脉粥样硬化的茶多酚组合物
WO2017204475A1 (ko) * 2016-05-24 2017-11-30 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
EP3251662A1 (en) * 2016-06-07 2017-12-06 Tolerogenics S.à.r.l. Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy
US10993917B2 (en) * 2016-12-30 2021-05-04 Agency For Science, Technology And Research Nanocomplex
KR101810156B1 (ko) * 2017-02-27 2017-12-19 인제대학교 산학협력단 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물
KR20200100028A (ko) * 2017-07-20 2020-08-25 암리 에스에스씨아이 엘엘씨 에피갈로카테킨 갈레이트의 무정형 분산물
CN107501584A (zh) * 2017-08-30 2017-12-22 天津工业大学 一种新型复合膜的制备方法
KR102158730B1 (ko) * 2018-04-02 2020-09-22 주식회사 옵티팜 세포 피막화용 알지네이트 미세캡슐 및 이의 제조방법
TWI764186B (zh) 2018-06-15 2022-05-11 漢達生技醫藥股份有限公司 激酶抑制劑之鹽類及其組合物
KR20200036774A (ko) * 2018-09-28 2020-04-07 주식회사 삼양바이오팜 독소루비신을 유효성분으로 하는 조성물 및 그 제조 방법
JP2022510986A (ja) * 2018-12-12 2022-01-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ヒアルロン酸およびエピガロカテキン－３－ｏ－没食子酸のコンジュゲートおよびナノ粒子ならびにその使用
CN109820815B (zh) * 2019-02-15 2022-02-08 山东师范大学 一种具有pH响应的姜黄素胶束水凝胶及其制备方法
US11596643B2 (en) * 2019-06-18 2023-03-07 Sichuan Yingrui Pharmaceutical Technology Company Pectin-adriamycin conjugate as well as preparation method and use thereof
CN115461354A (zh) 2020-02-14 2022-12-09 长庚医疗财团法人林口长庚纪念医院 用于分子缀合或改造的串联重复癌症靶向肽及其在癌症治疗诊断学中的用途
CN113368080B (zh) * 2020-02-25 2023-11-17 香港中文大学 稳定的、生物粘附的、扩散限制性团聚体
WO2023043367A2 (en) * 2021-09-15 2023-03-23 Agency For Science, Technology And Research Green tea-based nanocomplexes for eye disease
WO2023076220A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Conjugates having antifouling nanoparticles and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074662A2 (en) * 1999-06-07 2000-12-14 University Of Sheffield Arthritis treatment
WO2006116532A2 (en) * 2005-04-28 2006-11-02 University Of Massachusetts Lowell Synthesis of oligo/poly(catechins) and methods of use
EP1888651B1 (en) * 2005-05-20 2014-07-30 Agency for Science, Technology and Research Aldehyde conjugated flavonoid preparations
KR101576310B1 (ko) * 2007-10-23 2015-12-09 에이전시 포 사이언스, 테크놀로지 앤드 리서치 세포에 항암제를 전달하는 방법
SG10201501829YA (en) 2010-03-11 2015-05-28 Agency Science Tech & Res Anti-cancer agent delivery vehicles capable of improved loading
JP2012005413A (ja) * 2010-06-24 2012-01-12 Osamu Numata 高分子ポリフェノールを含有する発酵茶抽出物の調製方法
US20140294724A1 (en) * 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
EP3041830B1 (en) 2013-09-03 2023-10-25 Agency For Science, Technology And Research Polymer-flavonoid conjugates and hydrogels for biomedical applications
CA2902811A1 (en) * 2014-01-24 2015-07-30 Linde Process Plants, Inc. Methods for separating hydrocarbon gases
US10052307B2 (en) 2014-05-09 2018-08-21 Agency For Science, Technology And Research Micellar nanocomplex

Also Published As

Publication number Publication date
JP2017518280A (ja) 2017-07-06
CA2948460A1 (en) 2015-11-12
IL248632B (en) 2021-03-25
SG11201609333YA (en) 2016-12-29
CA2948460C (en) 2020-10-13
BR112016026260A2 (pt) 2021-08-03
AU2015256667B2 (en) 2018-04-19
CN106659708B (zh) 2022-05-10
UA118479C2 (uk) 2019-01-25
AU2015256667C1 (en) 2018-07-05
EP3139915A4 (en) 2017-12-20
CU20160164A7 (es) 2017-05-10
EP3139915B1 (en) 2020-11-04
US10052307B2 (en) 2018-08-21
US20190008830A1 (en) 2019-01-10
KR102102093B1 (ko) 2020-04-17
KR20170007780A (ko) 2017-01-20
JP6307631B2 (ja) 2018-04-04
SA516380256B1 (ar) 2021-02-25
ZA201608424B (en) 2019-12-18
ES2847602T3 (es) 2021-08-03
CN106659708A (zh) 2017-05-10
KR20190095510A (ko) 2019-08-14
AU2015256667A1 (en) 2016-11-17
US20170258926A1 (en) 2017-09-14
IL248632A0 (en) 2017-01-31
WO2015171079A1 (en) 2015-11-12
US10463646B2 (en) 2019-11-05
EA035820B1 (ru) 2020-08-17
CU24520B1 (es) 2021-06-08
MX2016014606A (es) 2017-08-24
EP3139915A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
EA201692213A1 (ru) Мицеллярный нанокомплекс
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201890204A1 (ru) Антибактериальные соединения
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
EA201690371A1 (ru) Пиридазиноновые соединения и их применение
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
EA201591451A1 (ru) Модуляторы flap

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU